Skip to main navigation
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • About
    • Executive Management
    • Scientific Advisory Board
    • Board of Directors
  • Our Science
    • HGF/c-Met Pathway
    • Acute Kidney Injury
    • Acute Lung Injury
    • CNS Injury
  • Pipeline
    • ANG-3777
    • ANG-3070
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
    • Analyst Coverage
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Governance
    • Investor Resources
      • Investor Contact
      • Investor FAQs
      • Email Alerts
  • Publications
  • Careers
  • Contact
  • LinkedIn
  • Twitter

Events & Presentations

Presentations
Corporate Presentation
Upcoming Events
HC Wainwright Global Life Sciences Conference
March 9, 2021 7:00 AM EST
Click here for webcast
Add to Outlook
Add to Google Calendar
Oppenheimer 31st Annual Healthcare Conference
March 18, 2021 10:40 AM EDT
Click here for webcast
Add to Outlook
Add to Google Calendar

Angion - Investor Tools

  • Print Page
  • Email Alerts
  • RSS Feeds

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© Angion. All Rights Reserved.
Legal and Privacy Policy

SAN FRANCISCO| NEW YORK | BOSTON

  • LinkedIn
  • Twitter